CONNECT 4 STRATEGIES, LLC

View full entity profile (contributions, contracts, SEC) →

Lobbying Income

$3.1M

Filings

242

Unique Clients

Active Period

2014–2026

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2026	—	3	1
2025	—	8	2
2024	—	8	2
2023	$120,000	8	2
2022	$190,000	21	6
2021	$210,000	28	7
2020	$390,000	29	7
2019	$520,000	32	8
2018	$470,000	31	8
2017	$495,000	40	8
2016	$310,000	16	4
2015	$375,000	14	3
2014	$60,000	4	2

Top Clients

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
OREXO US INC	$1,400,000	48	2014–2025
RECORDATI RARE DISEASES	$460,000	26	2017–2022
USAGAINSTALHEIMER'S	$235,000	15	2017–2019
Mast Therapeutics, Inc.	$205,000	11	2014–2016
AKCEA THERAPEUTICS, INC.	$190,000	12	2019–2021
STARKEY HEARING TECHNOLOGIES	$180,000	5	2017
USAGINASTALZHEIMER'S NETWORK	$160,000	13	2017–2019
FCS FOUNDATION	$160,000	14	2019–2022
THERABRON THERAPEUTICS, INC	$60,000	8	2015–2016
FERRING PHARMACEUTICALS, INC.	$60,000	14	2019–2022
BIOMARIN PHARMACEUTICAL INC.	$30,000	4	2016
IMARA, INC.	—	10	2017–2018
THE HAYSTACK PROJECT	—	38	2018–2026
NATIONAL EATING DISORDER ASSOCCIATION	—	6	2017–2018
ALPHA-1 FOUNDATION	—	11	2020–2022
BINGE EATING DISORDER ASSOCIATION	—	7	2017–2018

Government Bodies Lobbied

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
SENATE	132
HOUSE OF REPRESENTATIVES	127
Centers For Medicare and Medicaid Services (CMS)	49
Food & Drug Administration (FDA)	34
Health & Human Services, Dept of (HHS)	8

Top Issues Lobbied

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	102
Pharmacy	Pharmacy	55
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	10

Bills Explicitly Cited (25)

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · fourth_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184 and S 4071

Client expense: — · Firm income: —

Matched citations: HR 1184

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · fourth_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184 and S 4071

Client expense: — · Firm income: —

Matched citations: S 4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · fourth_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: HR1184

H.R. 7567117th Congress

To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.

2022 · fourth_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: HR7567

Show 21 more cited filings

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · fourth_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: S4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · third_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: HR1184

H.R. 7567117th Congress

To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.

2022 · third_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: HR7567

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · third_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: S4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · third_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184 and S 4071

Client expense: — · Firm income: —

Matched citations: HR 1184

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · third_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184 and S 4071

Client expense: — · Firm income: —

Matched citations: S 4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · second_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184 and S 4071

Client expense: — · Firm income: —

Matched citations: HR 1184

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · second_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184 and S 4071

Client expense: — · Firm income: —

Matched citations: S 4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · second_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: HR1184

H.R. 7567117th Congress

To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.

2022 · second_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: HR7567

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · second_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071 Access to Rare Indications Act HR7567

Client expense: — · Firm income: —

Matched citations: S4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · second_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071

Client expense: — · Firm income: —

Matched citations: HR1184

S. 4071117th Congress

Helping Experts Accelerate Rare Treatments Act of 2022

2022 · second_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR1184 and S4071

Client expense: — · Firm income: —

Matched citations: S4071

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2022 · first_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184

Client expense: — · Firm income: $10,000

Matched citations: HR 1184

H.R. 7567117th Congress

To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.

2022 · first_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HR7567 The Access to Rare Indications Act HEART Act.

Client expense: — · Firm income: —

Matched citations: HR7567

S. 3532117th Congress

A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.

2022 · first_quarter · Client: OREXO US INC

Open original LDA filing ↗

Cited source text and reported amounts

Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.

Client expense: — · Firm income: $60,000

Matched citations: S3532

H.R. 1184117th Congress

Helping Experts Accelerate Rare Treatments Act of 2021

2021 · fourth_quarter · Client: FCS FOUNDATION

Open original LDA filing ↗

Cited source text and reported amounts

HEART Act HR 1184

Client expense: — · Firm income: $10,000

Matched citations: HR 1184

H.R. 7567117th Congress

To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.

2021 · fourth_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HR7567 The Access to Rare Indications Act HEART Act.

Client expense: — · Firm income: —

Matched citations: HR7567

S. 3532117th Congress

A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.

2021 · fourth_quarter · Client: OREXO US INC

Open original LDA filing ↗

Cited source text and reported amounts

Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.

Client expense: — · Firm income: $40,000

Matched citations: S3532

H.R. 7567117th Congress

To amend chapter 77 of title 5, United States Code, to clarify certain due process rights of Federal employees serving in sensitive positions, and for other purposes.

2021 · third_quarter · Client: THE HAYSTACK PROJECT

Open original LDA filing ↗

Cited source text and reported amounts

HR7567 The Access to Rare Indications Act HEART Act.

Client expense: — · Firm income: —

Matched citations: HR7567

S. 3532117th Congress

A bill to require the imposition of sanctions with respect to Ansarallah and its officials, agents, or affiliates for acts of international terrorism.

2021 · third_quarter · Client: OREXO US INC

Open original LDA filing ↗

Cited source text and reported amounts

Legislative and regulatory issues pertaining to Orexo Implementation of the SUPPORT act. Access to Digital Therapeutics (S3532) MAT Digital Therapeutics Support Recovery Act.

Client expense: — · Firm income: $40,000

Matched citations: S3532

Source: Senate LDA

CONNECT 4 STRATEGIES, LLC — Lobbying Disclosure | Poliscope